Memon et al. showed an association of chronic and upregulated IFN signaling with acquired resistance in tumors from NSCLC patients who developed resistance to PD-1/PD-L1 blocking therapy [39]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.